- Home
- GRO vs IGMS Comparison
GRO vs IGMS Comparison
Compare GRO & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRO
- IGMS
- Stock Information
- Founded
- GRO 2006
- IGMS 1993
- Country
- GRO Canada
- IGMS United States
- Employees
- GRO N/A
- IGMS N/A
- Industry
- GRO
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- GRO
- IGMS Health Care
- Exchange
- GRO NYSE
- IGMS Nasdaq
- Market Cap
- GRO 95.8M
- IGMS 82.1M
- IPO Year
- GRO 2024
- IGMS 2019
- Fundamental
- Price
- GRO $3.06
- IGMS $1.17
- Analyst Decision
- GRO Strong Buy
- IGMS Hold
- Analyst Count
- GRO 1
- IGMS 8
- Target Price
- GRO $17.00
- IGMS $6.14
- AVG Volume (30 Days)
- GRO 174.8K
- IGMS 200.2K
- Earning Date
- GRO 05-03-2025
- IGMS 03-06-2025
- Dividend Yield
- GRO N/A
- IGMS N/A
- EPS Growth
- GRO N/A
- IGMS N/A
- EPS
- GRO N/A
- IGMS N/A
- Revenue
- GRO N/A
- IGMS $2,679,000.00
- Revenue This Year
- GRO N/A
- IGMS $134.71
- Revenue Next Year
- GRO N/A
- IGMS $74.27
- P/E Ratio
- GRO N/A
- IGMS N/A
- Revenue Growth
- GRO N/A
- IGMS 25.77
- 52 Week Low
- GRO $2.18
- IGMS $1.12
- 52 Week High
- GRO $15.00
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- GRO N/A
- IGMS 33.91
- Support Level
- GRO N/A
- IGMS $1.17
- Resistance Level
- GRO N/A
- IGMS $1.31
- Average True Range (ATR)
- GRO 0.00
- IGMS 0.08
- MACD
- GRO 0.00
- IGMS 0.04
- Stochastic Oscillator
- GRO 0.00
- IGMS 14.52
About GRO BRAZIL POTASH CORP
Brazil Potash Corp is a mineral exploration and development company with a potash mining project located in the state of Amazonas, Brazil. The company's technical operations are based in Autazes, Amazonas, Brazil, and Belo Horizonte, Minas Gerais, Brazil. The operating activities of the company includes focusing on the extraction and processing of potash ore from underground mine and selling and distributing the processed potash in Brazil.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.